A small pilot study published in BMC Psychiatry found that a non-invasive brain stimulation technique called DIFS (Deep Intracranial Frequency Stimulation) produced statistically significant reductions in self-injury behaviors and depressive symptoms in female adolescents with non-suicidal self-injury. The findings add to growing evidence that high-frequency brain stimulation may help treat mental health conditions, though researchers emphasize that much larger, more rigorous studies are needed before the approach can be considered ready for widespread clinical use .

What Did the Study Show About Brain Changes?

The research evaluated six female adolescent patients who received 21 days of 77.5 Hz (a specific frequency of electrical stimulation) at 15 milliamps of power using a Nexalin Technology device. According to the published findings, patients showed measurable improvements across multiple measures .

• Depression Scores: All six patients showed significant improvement in depression scores on the HAMD-24 scale, a validated tool for measuring depressive symptoms, with benefits persisting through follow-up assessments.
• Self-Injury Reduction: Five of the six patients (83.3%) met the study's response criterion for self-injury outcomes, with significant reductions in both self-injury thoughts and actual behaviors as measured by the OSIC scale.
• Brain Network Changes: The study used TMS-EEG (transcranial magnetic stimulation combined with electroencephalography) to measure changes in brain activity across emotional control networks, including the Default, Limbic, Salience/Ventral Attention, and Control networks.
• Additional Benefits: Patients also showed improvements in anxiety and sleep quality measures, with no significant adverse effects reported except for one mild headache that resolved quickly.

The neurophysiological findings are noteworthy because they provide objective evidence that the stimulation actually changes how different brain regions communicate with each other. These networks are known to be involved in rumination, emotional regulation, and self-injurious behavior, suggesting that the treatment works by modulating the brain systems underlying these conditions .

Why Are Researchers Cautious About These Results?

Despite the promising findings, the study has significant limitations that prevent immediate clinical application. The sample size of six patients is extremely small, making it difficult to know whether results would hold up in a larger, more diverse population. Additionally, the study lacked a sham control group (a placebo comparison) and did not use randomization, meaning some of the improvement could theoretically be due to placebo effect or natural recovery rather than the stimulation itself .

The study authors themselves described their findings as preliminary and explicitly called for larger randomized controlled trials to validate the approach. This is standard scientific practice: pilot studies like this one generate promising signals that justify investment in bigger, more rigorous research, but they cannot prove that a treatment works .

How Does This Fit Into Broader Mental Health Research?

This publication represents part of a larger research effort by Nexalin to establish scientific evidence for its DIFS technology across multiple mental health conditions. The company has published peer-reviewed studies examining the approach for insomnia, depression, traumatic brain injury (TBI), post-traumatic stress disorder (PTSD), Alzheimer's disease, and attention-deficit/hyperactivity disorder (ADHD) .

"This publication is important because it extends the scientific case for Nexalin's high-gamma DIFS technology into one of the most urgent and difficult-to-treat populations in mental health. What stands out is not just the symptom improvement, but the objective TMS-EEG evidence showing changes in the brain networks associated with rumination, emotional regulation, and self-injurious behavior," stated David Owens, Chief Medical Officer of Nexalin.

David Owens, MD, Chief Medical Officer of Nexalin

Non-suicidal self-injury (NSSI) is particularly challenging to treat because current therapeutic options, including psychotherapy and medication, do not work for all patients. Adolescents with NSSI face elevated risk for suicidal behavior and other mental health complications, making new treatment approaches potentially valuable if they prove effective in larger studies .

What Are the Next Steps for This Research?

The company has announced plans to launch a larger, more rigorous trial called HALO Clarity to evaluate the technology for insomnia treatment, with plans to seek FDA approval through a de novo pathway (a regulatory process for novel medical devices). The success of that trial could provide a template for how to design and conduct larger studies of DIFS for other conditions, including self-injury and depression .

For now, the key takeaway is that this pilot study provides encouraging preliminary evidence that warrants further investigation, but it does not yet prove that the treatment is safe and effective enough for routine clinical use. Patients and families interested in novel treatments for self-injury or depression should discuss options with their healthcare providers and be cautious about seeking unproven therapies outside of formal clinical trials.